Invitrall develops novel in vitro diagnostic tests for infectious diseases, focusing on rapid and accurate detection. Their technology aims to improve patient outcomes by enabling earlier diagnosis and more effective treatment strategies.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic tests for infectious diseases can be slow and lack the sensitivity needed for early detection. This delay in diagnosis can lead to delayed treatment, potentially worsening patient outcomes and increasing the risk of disease transmission.
Solution
Invitrall is developing a suite of in vitro diagnostic tests designed for the rapid and accurate detection of infectious diseases. Their focus is on improving patient outcomes through earlier diagnosis, enabling more effective and timely treatment interventions. By providing faster and more reliable results, Invitrall aims to empower healthcare professionals to make informed decisions and improve patient management in infectious disease scenarios.
Target Audience
The primary target audience includes hospitals, clinics, diagnostic laboratories, and healthcare providers involved in the diagnosis and management of infectious diseases.
Features
- Rapid turnaround time for test results, enabling quicker clinical decision-making.
- High sensitivity and specificity to minimize false positives and negatives.
- User-friendly design for ease of use in various clinical settings.